🏆 Finalist — NIH Data Sharing Index (“S-Index”) Challenge

Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors

JAAD International(2024)10.1016/j.jdin.2024.11.004Source: DataRank Database

NRAS tumor mutations are associated with reduced odds of dermatologic adverse events in patients with metastatic melanoma receiving immune checkpoint inhibitors is a research paper published in JAAD International (2024). On theSindex it has a DataRank of 0.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access0 citations

Cite:

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: goldTopics (11)IDs (PubMed)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Jordan T. Said ORCID,Elliot H. Akama‐Garren ORCID,Nicole Trepanowski ORCID,Ai‐Tram N. Bui ORCID,Anita Giobbie‐Hurder ORCID

Live enrichment

PubMed:39830992

National Institutes of Health

Grant: 3T32GM144273-03S1

Medical Scientist Training Program

National Institutes of Health

Grant: 1F30AI160909-01

Follicular helper T cells as drivers of epitope spreading

National Institutes of Health

Grant: 3T32GM007753-41S1

Medical Scientist Training Program

National Institutes of Health

Grant: 5T32AI007529-09

TRAINING IN TRANSPLANTATION BIOLOGY

goldLicense: CC BY NC ND

https://doi.org/10.1016/j.jdin.2024.11.004

https://pubmed.ncbi.nlm.nih.gov/39830992

http://dx.doi.org/10.1016/j.jdin.2024.11.004

https://doaj.org/article/ab6bd0bb965a40a99d8de0f843cdf78e

Fields of Study

03 medical and health sciences0302 clinical medicine

Keywords

atezolizumabanti-PDL-1RL1-803Research Letteranti-PD-1avelumabcemiplimabdAEDermatology